OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million on July 8, 2020. OncoDNA will acquire all shares of IntegraGen at an offer per share of €2.2. The transaction is structured as a tender offer. The transaction is subject to the approval of the Autorité des Marchés Financiers and applicable regulations to foreign investment control in France. The offer was approved on a unanimous basis by all members of the Board of both companies. As of September 15, 2020, the transaction was approved by AMF. At the end of the offer OncoDNA holds 3,897,110 IntegraGen shares, representing 58.92% of the capital. The offer shall be opened at the end of the third quarter of 2020. On September 16, 2020, Oncodna formally launched the tender offer and will be open for acceptances in the next 25 days. The Autorité des marchés financiers announced the reopening of the friendly public tender offer for IntegraGen shares, from October 30 to November 12, 2020, following the success of the first offer, closed on October 21, 2020. ODDO BHF SCA acted as financial advisor, Alexis Hojabr, Franck De Vita, Alexandre Jaurett, Orion Berg, Jean-Luc Champy and Clara Hainsdorf of White & Case LLP Avocats-Advocaten and Hadrien Chef, Marie Canivet, Benjamin Docquir and Thierry Viérin of Osborne Clarke BV CVBA acted as legal advisors for OncoDNA. Portzamparc acted as financial advisor, Olivier Grivillers of Crowe HAF acted as fairness opinion provider and Jones Day acted as legal advisor for IntegraGen. OncoDNA SA completed the acquisition of 64.7% stake in IntegraGen SA (ENXTPA:ALINT) for €9.4 million on November 12, 2020. OncoDNA now owns 4.27 million shares in IntegraGen.